[124I]FIAU PET-CT Scanning in Diagnosing Osteomyelitis in Patients With Diabetic Foot Infection
Status: | Terminated |
---|---|
Conditions: | Infectious Disease, Orthopedic, Diabetes |
Therapuetic Areas: | Endocrinology, Immunology / Infectious Diseases, Orthopedics / Podiatry |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/21/2016 |
Start Date: | April 2013 |
End Date: | February 2014 |
Exploration of the Use of [124I]FIAU Positron Emission Tomography-Computed Tomography Scanning in Diagnosing Osteomyelitis in Patients With Diabetic Foot Infection.
This protocol will evaluate the sensitivity and specificity of [124I]FIAU as a diagnostic
imaging agent for the detection of osteomyelitis in patients with diabetic foot infection.
imaging agent for the detection of osteomyelitis in patients with diabetic foot infection.
Inclusion Criteria:
1. Male and female patients >/= 18 years on the day of signing consent.
2. A diagnosis of diabetes mellitus, type I or II, as evidenced either by HbA1c>6.5% or
receipt of antidiabetic medication at time of enrollment.
3. Ability to provide informed consent
4. An inframalleolar ulcer of perfusion, extent/size, depth/tissue loss, infection and
sensation (PEDIS) grade 2 or 3. At the discretion of the Investigator, patients with
PEDIS grade 4 infections may be included if they are sufficiently stable.
5. For females of childbearing potential, a negative urine pregnancy test on the day of
dosing.
6. For females of childbearing potential, a willingness to use 2 methods of
contraception for 30 days after receiving [124I]FIAU.
7. Ability to return for all study assessments.
8. Clinically euthyroid, or on stable thyroid replacement therapy.
Exclusion Criteria:
1. Patients who ar unable to comply with study requirements.
2. Indication, in the opinion of the principal Investigator for urgent surgery that
would preclude the time needed for PET-CT scanning, or clinical instability that
precludes PET-CT scanning.
3. History of an inherited mitochondrial disorder (eg. Leber's hereditary neuropathy,
neuropathy, ataxia, retinitis pigmentosa and ptosis [NARP], myoneurogenic
gastrointestinal encephalopathy [MNGIE], myocolonic epilepsy with ragged red fibers
[MERFF] and mitochondrial myopathy, encephalomyopathy, lactic acidosis and
stroke-like syndrome [MELAS])
4. Alanine aminotransferase (ALT)>5x Upper Limit of Normal (ULN) OR aspartate
aminotransferase (AST) >5x ULN.
5. Body mass that exceeds the rating of the CT table.
6. Hypersensitivity to iodine.
7. Pregnant or breast-feeding.
8. Any condition that would put the patient at unreasonable risk in the opinion of the
Investigator.
We found this trial at
3
sites
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
Click here to add this to my saved trials
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials
University of Arizona The University of Arizona is a premier, public research university. Established in...
Click here to add this to my saved trials